# Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

> **NCT02879513** · PHASE3 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 290 (estimated)

## Conditions studied

- Invasive Ductal Breast Cancer
- Tubular Breast Cancer
- Mucinous Breast Cancer
- Inflammatory Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** 5-fluoruracil

## Key facts

- **NCT ID:** NCT02879513
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2020-06
- **Final completion:** 2022-12
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2020-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02879513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02879513, "Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02879513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*